Opportunities for machine learning and artificial intelligence in physiologically-based pharmacokinetic (PBPK) modeling
Advanced Drug Delivery Reviews · 2025
DOI: 10.1016/j.addr.2025.115716 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2025. Verfasst von Anne M Talkington und 3 weiteren Autor:innen. Beteiligte Einrichtung: Applied and Computational Mathematics Division, National Institute of Standards and Technology, Gaithersburg, MD, USA; Division of Pharmacokinetics, …. Hauptthemen laut MEDLINE: Machine Learning, Models, Biological, Artificial Intelligence, Pharmacokinetics. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, University at Buffalo, University of North Carolina.
Abstract (Originalsprache)
Physiologically-based pharmacokinetic (PBPK) modeling is a powerful tool for quantitating and understanding the fate of drug and drug carriers in complex living systems. It is particularly valuable in situations where data are difficult to obtain due to cost, time, or ethical constraints. Recent advances in PBPK modeling have greatly improved their accuracy in modeling in vivo and clinical data, especially in special populations (e.g., pediatric and geriatric subjects), which consequently enhanced their utility in drug development. Nevertheless, current PBPK models remain limited by our ability to ascertain complex biological mechanisms and/or physiological processes, often resulting in many critical but unknown parameters or parameters with large uncertainty. Machine learning (ML) and applications of broader artificial intelligence (AI) tools that facilitate parameter estimation, model learning, database mining, and uncertainty quantification not only offer the potential to address the shortcomings of PBPK modeling, but also introduce opportunities for enabling earlier use of PBPK modeling in the drug development process. Here, we summarize ML-influenced advances in PBPK modeling and discuss our expectations of the likely avenues for future ML/AI contributions to PBPK modeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Applied and Computational Mathematics Division, National Institute of Standards and Technology, Gaithersburg, MD, USA; Division of Pharmacokinetics, Pharmacodynamics, and Systems Pharmacology, Department of Pharmaceutic…
- Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, NC, USA.
- Applied and Computational Mathematics Division, National Institute of Standards and Technology, Gaithersburg, MD, USA.
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA; Department of Biomedical Engineering, University of North Carolina, Chapel Hi…
Förderung
- NIGMS NIH HHS
- University at Buffalo
- University of North Carolina
- Alamogordo Music Theatre
- National Institute of Standards and Technology
- Sveriges Kommuner och Landsting
- The University of North Carolina at Chapel Hill Eshelman School of Pharmacy
- National Institutes of Health
Zitieren
APA
Talkington, A. M., Cao, Y., Kearsley, A. J., & Lai, S. K. (2025). Opportunities for machine learning and artificial intelligence in physiologically-based pharmacokinetic (PBPK) modeling. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2025.115716
Vancouver
Talkington AM, Cao Y, Kearsley AJ, Lai SK. Opportunities for machine learning and artificial intelligence in physiologically-based pharmacokinetic (PBPK) modeling. Advanced Drug Delivery Reviews. 2025. doi:10.1016/j.addr.2025.115716
BibTeX
@article{Talkington2025,
author = {Talkington, Anne M and Cao, Yanguang and Kearsley, Anthony J and Lai, Samuel K},
title = {Opportunities for machine learning and artificial intelligence in physiologically-based pharmacokinetic (PBPK) modeling},
journal = {Advanced Drug Delivery Reviews},
year = {2025},
doi = {10.1016/j.addr.2025.115716}
}
EUVIMED